Xenon Pharmaceuticals Inc. - Common Stock (XENE)

Q1 2021 13F Holders as of 3/31/2021

Type / Class: Equity / Common Stock
Shares outstanding: 77.3M
Number of holders: 88
Total 13F shares, excl. options: 32.9M
Shares change: +4.95M
Total reported value, excl. options: $590M
Value change: +$88.7M
Number of buys: 42
Number of sells: -27
Price: $17.90

Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q1 2021

94 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q1 2021.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 32.9M shares of 77.3M outstanding shares and own 42.6% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (3.65M shares), BVF INC/IL (3.48M shares), FMR LLC (3.09M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.55M shares), ORBIMED ADVISORS LLC (2.5M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.49M shares), Capital International Investors (1.06M shares), NEA Management Company, LLC (992K shares), Capital World Investors (964K shares), and Bank of New York Mellon Corp (958K shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

Investor	Option	Weight %	Change %	Value $	* Price $	Shares	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.